Gender /Age | Smoking indexa/Quitting time | Comorbidity | PFT FEV1/MVV/DLCO (% pred) | Type and history of ILD | Image feature and range of ILD | Pathology and TNM stage | Surgery | Operation time (min) | Intraoperative blood loss (ml) | Onset of AE-ILD | Treatment | Outcome |
---|---|---|---|---|---|---|---|---|---|---|---|---|
M/74 | 30/180mo | None | 80/84/53 | IPF/3mo | UIP/whole lung field | SCLC/III-a | L + SLND/VATS | 105 | 350 | POD 2 | Glucocorticoid /IMV | Died, POD 15 |
M/73 | 50/36mo | COPD, CHD | 63.6/48.4/57.4 | IPF/36mo | UIP/whole lung field | SCC/Ia2 | W + SLND/VATS | 75 | 30 | POD 52 | NIV | Improve |
M/76 | 75/0.5mo | COPD, CHD, AF, renal carcinoma | 92.8/93.4/64.9 | IPF/36mo | UIP/bilateral subpleural area | SCLC/Ia1 | W + SLND /VATS | 60 | 20 | POD 5 | Glucocorticoid | Improve |
M/60 | 150/1mo | CHD, DM | 69/86/67 | IPF/240mo | UIP/bilateral subpleural area | SCLC/IIb | L + SLND /VATS | 160 | 200 | POD 3 | Glucocorticoid /NIV | Improve |
M/74 | 50/1mo | HTN, SS, glomerular nephritis | 88/134/66 | CTD-ILD/48mo | Non-UIP/bilateral subpleural area | SCLC/IIIa | L + SLND /VATS | 230 | 600 | POD 3 | Glucocorticoid /IMV | Died, POD 38 |
F/73 | non-smoker | HTN, SS | 60/92/64 | CTD-ILD/48mo | Non-UIP/bilateral subpleural area | IP | L/VATS | 160 | 600 | POD 3 | Glucocorticoid /NIV | Died, POD 13 |
M/70 | non-smoker | CHD, DM | 107.4/89/61.6 | IPF/unknown | UIP/bilateral subpleural area | IP | S + W/VATS | 100 | 50 | POD 30 | Glucocorticoid /NIV | Died, POD 60 |